Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 2,402 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the transaction, the chief executive officer now owns 662,692 shares in the company, valued at $27,110,729.72. This represents a 0.36 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Twist Bioscience Stock Performance
TWST stock traded up $0.65 during trading on Friday, reaching $39.77. 396,260 shares of the company's stock were exchanged, compared to its average volume of 992,561. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The firm has a market cap of $2.37 billion, a PE ratio of -11.77 and a beta of 2.15. The company's fifty day moving average price is $45.91 and its 200-day moving average price is $45.31. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience's revenue was up 24.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.75) EPS. On average, research analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.
Institutional Investors Weigh In On Twist Bioscience
A number of institutional investors have recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience in the third quarter valued at $34,000. Van ECK Associates Corp raised its position in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after acquiring an additional 267 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Twist Bioscience in the 4th quarter valued at about $43,000. GF Fund Management CO. LTD. bought a new position in shares of Twist Bioscience during the 4th quarter valued at about $58,000. Finally, US Bancorp DE grew its stake in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares during the last quarter.
Analyst Upgrades and Downgrades
TWST has been the subject of a number of recent analyst reports. Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird raised their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an "overweight" rating in a report on Monday, February 3rd. Finally, TD Cowen reaffirmed a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and a consensus price target of $54.40.
Get Our Latest Stock Report on Twist Bioscience
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Read More

Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.